{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-008698","form_type":"8-K","ticker":"MDGL","cik":"0001157601","company_name":"MADRIGAL PHARMACEUTICALS, INC.","filed_at":"2026-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.623016+00:00","generated_at":"2026-05-16T05:54:30.824373+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Madrigal gains full control over Rezdiffra patent term extensions from Roche","bullets":["Madrigal gets exclusive right to manage all patent term extensions for Rezdiffra, including Roche-owned and joint patents.","Royalty reduction on Rezdiffra net sales is deferred until expiration of certain patent term extensions that have been or could be filed.","Amendment modifies the 2008 Research, Development, and Commercialization Agreement with Roche.","Madrigal also obtains full rights over joint patent rights and know-how without consent or accounting to Roche."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-008698","json":"https://secwatch.observer/filing/0001104659-26-008698.json","markdown":"https://secwatch.observer/filing/0001104659-26-008698.md","text":"https://secwatch.observer/filing/0001104659-26-008698.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1157601/000110465926008698/0001104659-26-008698-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1157601/000110465926008698/tm264540d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T05:54:30.824373+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"031e80f3fdd8beab97b4f62f142b3ece3f045d79","claim":"MADRIGAL PHARMACEUTICALS, INC. amended First Amendment to the Research, Development, and Commercialization Agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (together, “Roche”) (effective 2026-01-29).","evidence_excerpt":"On January 29, 2026 (the “Effective Date”), Madrigal Pharmaceuticals, Inc. (the “Company”), F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (together, “Roche”) entered into the First Amendment (the “Amendment”) to the Research, Development, and Commercialization Agreement dated as of December 18, 2008 between the Company and Roche.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1157601/000110465926008698/0001104659-26-008698-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (together, “Roche”)"},{"label":"Effective","value":"2026-01-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}